SAN JOSE, CA, November 10, 2020 (GLOBE NEWSWIRE) - AnPac Bio-Medical Science Co, Ltd. ("AnPac Bio" or "The Company" or "We") (NASDAQ: ANPC), a biotech company operating In China and the United States, it announced today that the company has completed the FDA EUA- SARS-CoV-2 (COVID) -19) antibody verification test at the San Jose, California laboratory in November 2020 for the Roche Elecsys Anti Sars-COV-2 test, which is now Able to enter the commercial testing phase The company has also announced that COVID-19 antibody testing equipment has also completed its installation in the Philadelphia Lab. Anpac Bio has focused on developing and marketing COVID-19 testing products and services in both the US and China as COVID-19 cases continue to rise. 19 With no clear short-term and medium-term containment measures in sight, COVID-19 tests are likely to become long-term and widely required In addition, COVID-19 antibody testing is likely to become increasingly valuable as a measure of the potential effectiveness of COVID-19 vaccines, and in helping employers ensure office safety and productivity alongside AnPac Bio's vision and goal of developing and delivering products. And new testing services, the company is fully committed to qualifying and marketing COVID-19 tests in both the United States and China The verification and marketing of COVID-19 antibody tests in the United States is a major milestone for AnPac Bio, as this is the first commercial test in the United States from In addition to this, the company will also offer anti-COVID-19 antibody tests at the company’s laboratory in Philadelphia, where the COVID-19 antibody testing equipment has been installed for COVID-19 antibody tests, after all the appropriate requirements are met in the first half of In 2021 in addition to the COVID-19 testing products and services, the company's top priority continues to be the commercialization of cancer screening tests and a medical device, that is, Cancer Differentiation Analysis (CDA) technology, with the business of registering Class A medical device products The third CDA active in China And validation of the CDA test as a developed laboratory test (LDT) in the United States, CEO of AnPac Bio, D. Chris Yu commented: “The successful validation and commercialization of the COVID-19 antibody test in our laboratory in San Jose is a milestone. It indicates that AnPac Bio has entered the commercialization and revenue generation phase in the United States moreover, with the addition of the much larger Philadelphia lab (once verified in the laboratory) planned for both COVID-19 antibody tests and CDA detection tests. Cancer (Once the LDT test is approved), we will accelerate marketing and revenue growth in the US About AnPac BioAnPac Bio is a biotech company focused on early detection and detection of cancer, with 128 patents issued as of June 30, 2020 through Two accredited clinical laboratories in China and a CLIA and CAP accredited clinical laboratory and a CLIA registered clinical laboratory in the United States, AnPac Bio performs a range of cancer detection and detection tests, including CDA (Cancer Differentiation Analysis) and Biochemistry, Immunological Tests and Genomics According to Frost & Sullivan, AnPac Bio is ranked third in the world and first in China among companies offering the next generation of early detection and detection technology for cancer in terms of the number of clinical samples for cancer screening and detection, based on nearly 41,700 Clinical sample as in May 2020 AnPac Bio's CDA technology platform has been shown in retrospective verification studies to be able to detect risks of more than 20 different types of cancer with high sensitivity and specificity For more information, please visit: https://wwwAnpacbio.com for investor inquiries And the media, please contact: Company: Phil Case, Marketing and Investor Relations Tel: 1-267-810-6776 (United States) Email: phil_case @ AnPacbiocomInvestor Relations: Ascent Investor Relations LLC Tina Xiao, President's Phone: 1-917-609 -0333 (United States) Email: tina [email protected]
Safe Harbor Statement - This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act 1933 and MA Article 21 of the Securities Law of 1934 These forward-looking statements were prepared in accordance with the provisions of the "safe harbor" of the Securities Litigation Reform Act 1995 and relate to the future financial and operational performance of the company. The company attempted to define forward-looking statements through terms including "believed," " Estimates, “Expect”, “Expect”, “Plans”, “Projects”, “Intent”, “Potential”, “Objective”, “Objective”, “Forecast”, “Expectations”, “Research”, “Objective”, Objective, Assumption, Thinking, Continuation, Situation, Prediction, Probability, May, May, May, Will, Should, or Approximately "Or other words that convey uncertainty about future events or outcomes to determine these forward-looking statements. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, which are difficult or impossible to predict." Accurately, many of them are outside the company’s control. This data also includes known and unknown risks, uncertainties and other factors that may cause it to be Actual company results are materially different from those expressed or implied through any forward-looking statement that includes known and unknown risks, uncertainties and other factors, including but not limited to the implementation of our business model and our growth strategies; Trends and competition in the cancer screening market; Our expectations regarding the demand and market acceptance of our cancer screening and detection tests and our ability to expand our client base; Our ability to obtain and maintain intellectual property protection for our CDA technology and our continuous research and development to keep pace with technological developments; Our ability to obtain and maintain regulatory approvals from the relevant NMPA, FDA, and U.S states that our laboratories are accredited or accredited by authorities including the CLIA; Developing our future business, financial condition, results of operations, and ability to obtain cost-effective financing; Potential changes to government regulations; General economic and trade conditions in China and elsewhere; Our ability to recruit and maintain key employees; Our relationship with our partners and major clients; The duration of the outbreak of the Coronavirus and its potential negative impact on economic conditions, financial markets, our business and our financial performance, such as the result of reduced commercial activities due to quarantine and travel restrictions imposed by China, Q and many other countries around the world to contain the spread of the virus In addition, all forward-looking statements are subject to "Risk Factors" detailed from time to time in the Company's most recent annual report in Form 20-F and other filings with the US Securities and Exchange Commission due to these and other risks, uncertainties and assumptions, should not be relied unnecessarily on these forward-looking statements. In addition, These statements are only spoken as of the date of this press release, and except as may be required by law, the company does not undertake any obligation to review or update any forward-looking statements publicly for any reason.